Clinical Trials – October 12, 2026
Eight out of twelve patients with B-cell lymphoma and no remaining curative treatment options achieved a complete metabolic response after treatment with Elicera Therapeutics’ ELC-301. The results come from the now-completed Phase I part of the Swedish CARMA study.
Collaboration – October 12, 2026
Gothenburg-based OnDosis has entered a strategic collaboration with Adare Pharma Solutions, a US contract development and manufacturing organization (CDMO), to advance its lead ADHD program toward the US market. The partnership gives OnDosis commercial-scale manufacturing capacity in the US.
Clinical Trials – October 12, 2026
Zealand Pharma’s amylin analog petrelintide produced up to 9.2% mean weight loss after 28 weeks in people with overweight or obesity and type 2 diabetes, compared with 2.0% on placebo, in the Phase 2 ZUPREME-2 trial.
Biotech Business – October 12, 2026
Health Canada has approved Camurus’s Oczyesa XR, a once-monthly subcutaneous octreotide depot, for maintenance treatment of adults with acromegaly who have responded to and tolerated treatment with somatostatin analogs.
Business Award – October 12, 2026
Finnish AI pathology company Aiforia has won the public vote in the enterprise category of Vuoden Digiteko 2026 (Digital Innovation of the Year). The competition recognizes Finnish technology innovations with an exceptionally high impact on society, business, and people’s everyday lives.
Clinical Trials – October 9, 2026
Oncopeptides’ peptide drug conjugate crossed the blood-brain barrier in the first three patients treated in a glioblastoma study at Oslo University Hospital. Drug concentrations in the tumors matched preclinical models.
Clinical Trials – October 12, 2026
Eight out of twelve patients with B-cell lymphoma and no remaining curative treatment options achieved a complete metabolic response after treatment with Elicera Therapeutics’ ELC-301. The results come from the now-completed Phase I part of the Swedish CARMA study.
Clinical Trials – October 12, 2026
Zealand Pharma’s amylin analog petrelintide produced up to 9.2% mean weight loss after 28 weeks in people with overweight or obesity and type 2 diabetes, compared with 2.0% on placebo, in the Phase 2 ZUPREME-2 trial.
Clinical Trials – October 9, 2026
Oncopeptides’ peptide drug conjugate crossed the blood-brain barrier in the first three patients treated in a glioblastoma study at Oslo University Hospital. Drug concentrations in the tumors matched preclinical models.
Clinical Trials – October 7, 2026
Stockholm-based Pharmability has dosed the first patient in its Phase Ib study of TIR-C in atopic dermatitis, and the first cohort is now fully enrolled. The trial is the first in which the drug candidate is tested in humans.
Clinical Trials – October 7, 2026
Genmab and AbbVie’s bispecific antibody epcoritamab, added to standard R-CHOP chemoimmunotherapy, significantly improved progression-free survival in the Phase III EPCORE DLBCL-2 trial in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The companies say it is the first Phase III study of a bispecific antibody combination to show such a benefit in the frontline setting.
Clinical Trials – October 6, 2026
Boehringer Ingelheim’s survodutide, licensed from Danish Zealand Pharma, met both co-primary endpoints in the Phase III SYNCHRONIZE-2 trial in people with obesity or overweight and type 2 diabetes, with weight loss of up to 13.1% after 76 weeks versus 3.1% on placebo.
PharmaRelations
Are you a people-oriented Quality Assurance professional with a passion for business development, customer relationships and building successful teams?
Confidential
PharmaRelations is recruiting a Medical Device Auditor, on behalf of an innovative and fast-growing organization operating at the intersection of medical technology, regulatory compliance, and advanced digital solutions.
PharmaRelations
PharmaRelations is the Nordic market leader within talent services for the life science industry. We specialize in partnering with some of the top and most innovative organizations exclusively in the Life Science sector across our region. We add value to our clients and candidates with our consultancy services, outsourcing solutions and recruitment of specialists and leaders.
Karl Storz Endoskop Sverige AB
KARL STORZ är ett tyskt medicintekniskt företag som specialiserar sig på tillverkning och försäljning av endoskopisk utrustning och kirurgiska instrument. Företaget grundades 1945 i Tuttlingen av Dr. Karl Storz och har en lång historia av innovation inom medicinsk teknik.
PharmaRelations
Stillingen er 100 % remote med en forventet arbejdsbelastning på ca. 0-20 timer pr. måned, afhængigt af projektbehov.
PharmaRelations
You will have the opportunity to work in a team of PV specialists, helping our clients with the best solutions depending on their needs.
In a new job – October 7, 2026
After twelve years leading Norway’s oldest health cluster, Ketil Widerberg is leaving Oslo Cancer Cluster to head an AI initiative in healthcare at Oslo University Hospital.
In a new job – October 5, 2026
Alligator Bioscience has appointed its CFO, Johan Giléus, as CEO, effective January 1, 2027. He succeeds Søren Bregenholt, who will remain in the role until the end of the year.
In a new job – September 21, 2026
Bavarian Nordic has appointed Tarja Stenvall as President and Chief Executive Officer, effective 15 October. She succeeds Paul Chaplin, whose departure was announced earlier this year.
Career choice – September 14, 2026
From Stanford’s sunlit engineering quad to SciLifeLab’s brisk knowledge hub in Stockholm, Emma Lundberg works across two distinct innovation cultures. She sees lessons for Sweden in Silicon Valley’s close links between academia, investors, and industry, but also strengths at home that should not be lost.
Careers article – August 14, 2026
Returning to work after a long, relaxing vacation can be challenging. Here are some tips to make the transition easier and less stressful.
Careers article – July 19, 2026
Thomas Karikari’s career has taken him across three continents: from Ghana to the UK and Sweden, and then to the US. Now an Associate Professor at the University of Pittsburgh and one of Nature Index’s “rising stars in ageing research”, he is helping move Alzheimer’s blood biomarkers beyond individual markers and towards a more complete picture of disease biology.
Profiles in Business – October 4, 2026
Unbeknownst to her, Jessica Martinsson’s long and varied career in research and life sciences was preparing her for her newest and possibly most influential role.
Profiles in Business – September 30, 2026
Trine Bartholdy has spent her career at the intersection of science and finance, helping early discoveries grow into companies capable of shaping the future of health. Now, as AI and global competition are reshaping the conditions for European life sciences, she and her colleagues at the BioInnovation Institute (BII) leverage decades of expertise to usher young Nordic companies toward entrepreneurial success.
Profiles in Business – September 24, 2026
As HealthCap marks 30 years of life science investing, co-founder Björn Odlander reflects on the firm’s long-term approach, the journey from lab to patient, and Europe’s widening capital gap.
Financing – October 9, 2026
Orexo’s board has resolved on a rights issue of about SEK 250 million, subject to approval at an extraordinary general meeting on November 6. The money is mainly for the company’s development programs, including the first pivotal trial of OX640.
Pharma Business – October 8, 2026
Finnish Orion Pharma has signed an agreement with Qilu Pharma Europe for a pembrolizumab biosimilar for the European market. A day earlier, it dosed the first patient with ODM-216, its first biologic drug candidate to reach clinical testing.
Pharma Business – October 8, 2026
Bavarian Nordic has raised its full-year 2026 guidance for the third time this year. It now expects revenue of about DKK 6,100 million, up from about DKK 5,700 million, driven by higher sales of rabies vaccines, mainly in the US.
Collaboration – October 8, 2026
Aiforia has announced a commercial agreement with PathAI, a member of the Roche Group.
MedTech Business – October 5, 2026
Bergen-based Lifecare has manufactured its first functional continuous glucose monitoring (CGM) implants through its own operations, rather than through an external contract manufacturer. The company calls it an important step toward controlled manufacturing of its implantable sensor technology.
Collaboration – October 5, 2026
FluoGuide has entered a collaboration with medical technology company Leica Microsystems to advance precision surgery for brain tumors by combining its lead product, FG001, with Leica’s surgical microscope systems.
Biotech Business – October 6, 2026
Icelandic biosimilar developer Alvotech has signed a long-term manufacturing agreement with LOTTE Biologics for US-based production. A day earlier, the FDA approved a second production suite in Reykjavik for its Humira biosimilar SIMLANDI.
Biotech Business – October 6, 2026
Beactica Therapeutics has selected BEA-28 as a preclinical candidate in its TEAD program, which aims to develop new therapies for aggressive, hard-to-treat solid tumors, including cancers that have become resistant to existing treatments.
Biotech article – October 1, 2026
Södertälje-based Anocca has dosed the first patient in Sweden with its TCR-T cell therapy, which targets KRAS G12V mutations in pancreatic cancer. Sweden is the third European country where a patient has received the therapy.
Science Award – October 8, 2026
Per Uhlén, professor of cell signaling at Karolinska Institutet, has received the 2026 Lennart Nilsson Award. The award was presented on October 8 at KI’s professorial installation ceremony in Aula Medica, in recognition of his advanced microscopy methods that visualize the fundamental processes of life.
Science Award – October 7, 2026
Henri B. Kagan and Kenso Soai are awarded the Nobel Prize in Chemistry 2026 for discovering how chemical reactions can produce only one of two mirror-image molecules. Their work shows how this kind of asymmetry can arise, and has been decisive for chemists designing reactions to make pharmaceuticals.
Science Award – October 5, 2026
The Nobel Assembly at Karolinska Institutet has decided to award the 2026 Nobel Prize in Physiology or Medicine to Karl Deisseroth, Peter Hegemann and Georg Nagel for their discoveries concerning light-gated ion channels and optogenetics.
This site uses cookies
